Indinol Forto, capsules 60 pcs.

A selective modulator of estrogen receptors.

Indinol Forto is a universal corrector of pathological hyperplastic processes in the breast tissues. The therapeutic effect of Indinol Forto is based on its anti-estrogenic and antiproliferative action.

The main property of the drug Indinol Forto is its ability to induce selective death of the mammary gland cells with abnormally high proliferative activity.

The indolcarbinol in Indinol Forto modulates the cytochrome system so that the resulting cytochrome P450 isoform, CYP1A1, hydroxylates estrogens at the 2nd position to form 2-hydroxyestrone (2-HONE1).

The resulting metabolite is an estrogen receptor antagonist and blocks its activation by estrogens themselves as well as their dangerous metabolites, particularly 16-α-hydroxyestrone (16α-ONE1), whose proportion among metabolites is reduced.

In this way, the induction of estrogen-dependent genes is suppressed and the cell stops receiving excessive estrogen-dependent stimulation. The drug also blocks other signaling mechanisms (cytokines) that stimulate abnormal cell growth in breast tissues by inhibiting signaling cascades from the corresponding receptors.

Course use of the drug promotes reduction of intensity and disappearance of pain syndrome in the breast at cyclic mastalgia (mastodynia).

The use of the drug Indinol Forto does not lead to an increase in body weight. Indinol Forto is practically non-toxic (LD50>5 g/kg).

Indications

Breast pain, Reducing the risk of breast, ovarian and endometrial cancer

Cyclic mastalgia, including against the background of benign breast hyperplasia.

Active ingredient

Indolcarbinol

Composition

1 capsule:

indolcarbinol 0.2 g

Supplementary substances:

lactose monohydrate (milk sugar) – 0.14 g,

modified corn starch – 0.095 g,

microcrystalline cellulose – 0.064 g,

magnesium stearate – 0.001 g.

How to take, the dosage

Ingestion, 2 times a day, 200 mg. The daily dose of the drug is 400 mg.

The capsules are taken before meals.

The course of treatment lasts for 6 months.

Interaction

Indolcarbinol affects the activity of cytochrome Р450 isoenzymes, therefore caution should be exercised when using with drugs with metabolism of cytochrome Р450 isoenzymes (indirect anticoagulants, glucocorticosteroids, oral hypoglycemic agents, antiarrhythmic, antiepileptic, foxglove drugs, sex hormone drugs), because their doses may need to be adjusted.

Special Instructions

Indinol® Forto is unlikely to affect the ability to drive or operate machinery

Based on the characteristics of pharmacodynamics and the profile of adverse effects, it is unlikely that Indinol® Forto affects the ability to drive vehicles and operate machinery.

Contraindications

The drug should not be used in the presence of any of the following conditions:

• high sensitivity to the components of the drug;
• hereditary galactose intolerance, lactase deficiency or glucose-galactose malabsorption;
• pregnancy and breastfeeding period;
• children under 18 years of age.

.

Side effects

Reproductive system disorders: menstrual cycle disorders in the form of prolongation or shortening.

Digestive system disorders: pain in the epigastrium.

Laboratory findings: increased concentration of thyrotropic and follicle stimulating hormones, prolactin and estradiol, decreased concentration of creatinine, eosinophilia.

Other: decrease in body weight. If any of the side effects listed in the instructions worsen, or if you notice any other side effects not listed in the instructions, tell your doctor.

Overdose

Symptoms: possible symptoms of overdose include nausea, vomiting, diarrhea.

Treatment: no specific antidote is known.

In case of suspected overdose of Indinol® Forto, symptomatic therapy is recommended.

Pregnancy use

Indinol® Forto is contraindicated during pregnancy and breastfeeding.